Read by QxMD icon Read

Adv 36

Joshua A Hill, Bryan T Mayer, Hu Xie, Wendy M Leisenring, Meei-Li Huang, Terry Stevens-Ayers, Filippo Milano, Colleen Delaney, Mohamed L Sorror, Brenda M Sandmaier, Garrett Nichols, Danielle M Zerr, Keith R Jerome, Joshua T Schiffer, Michael Boeckh
Strategies to prevent active infection with certain double-stranded DNA (dsDNA) viruses after allogeneic hematopoietic cell transplantation (HCT) are limited by incomplete understanding of their epidemiology and clinical impact. We retrospectively tested weekly plasma samples from allogeneic HCT recipients at our center from 2007-2014. We used quantitative PCR to test for cytomegalovirus (CMV), BK polyomavirus (BKV), human herpesvirus 6B (HHV-6B), HHV-6A, adenovirus (AdV), and Epstein-Barr virus (EBV) between days 0-100 post-HCT...
February 16, 2017: Blood
Fu-Qiang Yang, Gui-Rong Rao, Gui-Qiang Wang, Yue-Qi Li, Yao Xie, Zhan-Qing Zhang, Cun-Liang Deng, Qing Mao, Jun Li, Wei Zhao, Mao-Rong Wang, Tao Han, Shi-Jun Chen, Chen Pan, De-Ming Tan, Jia Shang, Ming-Xiang Zhang, Yue-Xin Zhang, Ji-Ming Yang, Guang-Ming Chen
AIM: To assess the efficacy and safety of in vivo electroporation (EP)-mediated dual-plasmid hepatitis B virus (HBV) DNA vaccine vs placebo for sequential combination therapy with lamivudine (LAM) in patients with chronic hepatitis B. METHODS: Two hundred and twenty-five patients were randomized to receive either LAM + vaccine (vaccine group, n = 109) or LAM + placebo (control group, n = 116). LAM treatment lasted 72 wk. Patients received the DNA vaccine or placebo by intramuscular injection mediated by EP at weeks 12 (start of treatment with vaccine or placebo, SOT), 16, 24, and 36 (end of treatment with vaccine or placebo, EOT)...
January 14, 2017: World Journal of Gastroenterology: WJG
Jonathan W Goldman, Lucio Crino, Everett E Vokes, Esther Holgado, Karen Reckamp, Adam Pluzanski, David Spigel, Martin Kohlhaeufl, Marina Garassino, Laura Qm Chow, Scott Gettinger, David E Gerber, Libor Havel, Suresh S Ramalingam, Grace K Dy, William J Geese, Ang Li, Anne Blackwood-Chirchir, Diane Healey, Julie Brahmer, Gilberto Lopes
No abstract text is available yet for this article.
October 2016: Journal of Thoracic Oncology
Hui-Lian Wang, Xi Lu, Xudong Yang, Nan Xu
The relative efficacy of different strategies for chronic hepatitis B (CHB) patients with lamivudine resistance (LAM-R) has not yet been systematically studied. Clinical trials were searched in PUBMED, MEDLINE, EMBASE, and CNKI databases up to February 15, 2016. Nine trials including 764 patients met the entry criteria. In direct meta-analysis, TDF showed a stronger antiviral effect than any one of ETV, LAM/ADV, and ADV against LAM-R hepatitis B virus. LAM/ADV therapy was superior to ADV in suppressing viral replication...
2016: Gastroenterology Research and Practice
Igor M Ignatyev, Rustem V Akhmetzyanov
BACKGROUND: Aim of the study was to evaluate the long-term results of the monocusp valve formation in the common femoral vein (CFV) in patients presenting with avalvular deep veins (ADV) of the lower extremities. METHODS: A total of 36 patients (24 women and 12 men) at the age varying from 37 to 58 years old were given surgical treatment during the period from 2008 to 2014. 6 patients presented with congenital ADV while in the remaining 30 ADV was a consequence of the postthrombotic lesion in the valves with the complete recanalization and manifested deep venous axial reflux...
June 30, 2016: International Angiology: a Journal of the International Union of Angiology
Fabian Reche, Adrian Mancini, Anne-Laure Borel, Jean-Luc Faucheron
BACKGROUND: Gastric bypass procedures can potentially lead to middle and long-term complications (Podnos et al. Arch Surg 138(9):957-61, 2003). For several years, Roux-en-Y gastric bypass reversal procedures performed by laparotomy or laparoscopic way have been described in literature (Moon et al. Surg Obes Relat Dis 11(4):821-6, 2015). Major complications are anastomotic ulcers, anastomotic complications or functional disorder such as dumping syndrome, hypocalcemia, severe hypoglycemia, and malnutrition (Moon et al...
August 2016: Obesity Surgery
Sergio Conti, Massimo Moltrasio, Gaetano Fassini, Fabrizio Tundo, Stefania Riva, Antonio Dello Russo, Michela Casella, Benedetta Majocchi, Vittoria Marino, Pasquale De Iuliis, Valentina Catto, Salvatore Pala, Claudio Tondo
Introduction. Cryoballoon (CB) ablation has emerged as a novel treatment for pulmonary vein isolation (PVI) for patients with paroxysmal atrial fibrillation (PAF). The second-generation Arctic Front Advance (ADV) was redesigned with technical modifications aiming at procedural and outcome improvements. We aimed to compare the efficacy of the two different technologies over a long-term follow-up. Methods. A total of 120 patients with PAF were enrolled. Sixty patients underwent PVI using the first-generation CB and 60 patients with the ADV catheter...
2016: Cardiology Research and Practice
Iva I Podgorski, Laura Pantó, Tibor Papp, Balázs Harrach, Mária Benkö
Within the family Adenoviridae, presently Simian mastadenovirus A is the single species approved officially for monkey adenoviruses (AdVs), whilst the establishment of six further species (Simian mastadenovirus B to Simian mastadenovirus G) has been proposed in the last few years. We examined the genetic content and phylogenetic relationships of four Old World monkey (OWM) AdV types [namely simian AdV (SAdV)-8, -11, -16 and -19] for which it had been proposed that they should be classified into different AdV species: SAdV-11 to Human mastadenovirus G, and the other three viruses into three novel species...
July 2016: Journal of General Virology
Xiaoli Ge, Zhijun Han, Hongmin Chen, Juanjuan Cheng, Mingzhu Gao, Haibin Sun
BACKGROUND: To investigate the etiological and epidemiological features of acute respiratory infections among children in Wuxi, Jiangsu Province. METHODS: Nasopharyngeal swab specimens were collected from 340 pediatric patients from Wuxi Second People's Hospital from June 2012 to May 2014. Seven respiratory viruses including influenza virus A (FA), influenza virus B (FB), parainfluenza virus I (PIVI), parainfluenza virus II (PIVII), parainfluenza virus III (PIVIII), adenovirus (ADV), and respiratory syncytial virus (RSV) were detected using direct immunofluorescence method...
October 2015: Annals of Translational Medicine
Hyoung Su Kim, Hyung Joon Yim, Myoung Kuk Jang, Ji Won Park, Sang Jun Suh, Yeon Seok Seo, Ji Hoon Kim, Bo Hyun Kim, Sang Jong Park, Sae Hwan Lee, Sang Gyune Kim, Young Seok Kim, Jung Il Lee, Jin-Woo Lee, In Hee Kim, Tae Yeob Kim, Jin-Wook Kim, Sook-Hyang Jeong, Young Kul Jung, Hana Park, Seong Gyu Hwang
AIM: To evaluate the long-term efficacy adefovir (ADV)-based combination therapies in entecavir (ETV)-resistant chronic hepatitis B (CHB) patients. METHODS: Fifty CHB patients with genotypic resistance to ETV at 13 medical centers in South Korea were included for the analysis. All the patients received rescue therapy with the combination of ADV plus ETV (ADV/ETV, n = 23) or ADV plus lamivudine (LMV) (ADV/LMV, n = 27) for more than 12 mo. Patients were monitored at least every 3-4 mo during ADV-based combination therapy by clinical examination as well as biochemical and virological assessments...
October 14, 2015: World Journal of Gastroenterology: WJG
Huibin Ning, Kuan Li, Wei Li, Gangqiang Ding, Erhui Xiao, Zhongshan Mao, Yi Kang, Jia Shang
OBJECTIVE: To investigate the effects of adefovir dipivoxil (ADV) on blood phosphorus metabolism in patients with chronic hepatitis B (CHB). METHODS: Patients with hepatitis B surface antigen (HBsAg)-positive CHB were treated with ADV alone, ADV combined with interferon (IFN), or ADV combined with lamivudine (LAM). Changes in levels of calcium, phosphate, urea, and creatinine were assessed at treatment weeks 4, 12, 24, 48, 72 and 96. Statistical analysis was carried out with SPSS 16 software; influential factors were analyzed by ANOVA and non-conditional logistic regression analysis...
August 2015: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
Eleonora Ponterio, Lucio Gnessi
There is an epidemic of obesity starting about 1980 in both developed and undeveloped countries definitely associated with multiple etiologies. About 670 million people worldwide are obese. The incidence of obesity has increased in all age groups, including children. Obesity causes numerous diseases and the interaction between genetic, metabolic, social, cultural and environmental factors are possible cofactors for the development of obesity. Evidence emerging over the last 20 years supports the hypothesis that viral infections may be associated with obesity in animals and humans...
July 2015: Viruses
M A Sabin, D Burgner, R L Atkinson, Z Pei-Lun Lee, C G Magnussen, M Cheung, M Kähönen, T Lehtimäki, E Jokinen, T Laitinen, N Hutri-Kähönen, J S A Viikari, M Juonala, O T Raitakari
BACKGROUND/OBJECTIVES: Adenovirus-36 (Adv-36) infection is associated with exaggerated adipogenesis in cell culture and the development of obesity in animal models and humans, but a causal relationship remains unproven. Our objective was to determine whether serological evidence of Adv-36 infection in childhood and/or adulthood is associated with adult obesity. SUBJECTS/METHODS: Paired plasma concentrations of Adv-36 antibodies were measured by a novel enzyme-linked immunosorbent assay in a subgroup (n=449) of the Cardiovascular Risk in Young Finns Study in childhood (mean age 11...
November 2015: International Journal of Obesity: Journal of the International Association for the Study of Obesity
Yang Wang, Shuang Liu, Yu Chen, Sujun Zheng, Li Zhou, Fengmin Lu, Zhongping Duan
OBJECTIVE: Entecavir (ETV) added to adefovir (ADV) is recommended in the consensus for management of patients with ADV resistance. However, little attention has been focused on the delayed reduction of HBV DNA and dynamics of ADV-resistant variants during ADV-ETV combination rescue therapy in the clinical setting. We characterized the dynamics of viral load and resistant variants in nucleos(t)ide analogues (NAs)-naïve chronic hepatitis B (CHB) patients during antiviral treatment with ADV monotherapy followed by ADV-ETV combination therapy...
2015: International Journal of Medical Sciences
Yu-Wei Wang, Xuefeng Shan, Yao Huang, Haijun Deng, Wen-Xiang Huang, Da-Zhi Zhang, Juan Chen, Ni Tang, You-Lan Shan, Jin-Jun Guo, Ailong Huang
Adefovir dipivoxil (ADV) is used as first-line monotherapy or rescue therapy in chronic hepatitis B (CHB) patients. In this study, we sought to identify nucleotide changes in the reverse transcriptase (RT) of hepatitis B virus (HBV) at baseline and explore their predictive value for ADV antiviral response. Ultra-deep pyrosequencing (UDPS) was utilized to determine HBV genetic variability within the RT region at baseline and during a 48-week ADV therapy. According to the viral load at the end of ADV treatment, all patients were classified into responders (HBV DNA level reduction of ⩾ 3 log 10 IU/mL) and suboptimal responders (HBV DNA level reduction of <3 log 10 IU/mL)...
July 2015: Infection, Genetics and Evolution
Young E Chon, Bora Jin, Sang H Ahn, Seungtaek Kim, Nam D Kim, Jeon H Park, Chung M Nam, Kyun-Hwan Kim, Sun P Hong, Sung H Choi, Do Y Kim, Jun Y Park, Kwang-Hyub Han
BACKGROUND & AIMS: Analysing the mutation pattern of multidrug resistance (MDR) is important in the treatment of chronic hepatitis B (CHB). In this study, the evolutionary pattern of MDR mutations was investigated in patients receiving entecavir (ETV) rescue therapy. METHODS: Eight CHB patients with lamivudine (LAM)- and adefovir (ADV)-resistant mutations showing suboptimal response to ETV and to subsequent ETV-plus-ADV therapy were enrolled. The clonal evolution of the mutation pattern was investigated through direct sequencing, multiplex restriction fragment mass polymorphism (RFMP), and clonal analysis and the utility of these methods was compared...
November 2015: Liver International: Official Journal of the International Association for the Study of the Liver
Tan Seok Shin, Zeenathul Nazariah Allaudin, Mohd-Azmi Mohd Lila, Sheikh-Omar Abdul Rahman
Recombinant adenovirus encoding the VP2 gene of infectious bursal disease virus (ADV-VP2) has shown potent anti-tumour effects due to its capability of apoptotic induction in cancer cells. In the present study, human breast cancer cells MCF-7 and MDA-MB-231 were infected with ADV-VP2. The expression of VP2 protein was registered 4 h post-infection, particularly in MCF-7 cells. Multiple time-point DNA ladder assay demonstrated that ADV-VP2 infected MDA-MB-231 and MCF-7 cells endured apoptosis as early as 8 and 12 h post-infection, respectively...
January 2014: Molekuliarnaia Biologiia
Dan-Hong Yang, Yuan-Jun Xie, Nian-Feng Zhao, Hong-Ying Pan, Ming-Wei Li, Hai-Jun Huang
AIM: To assess the efficacy of tenofovir disoproxil fumarate (TDF) in lamivudine (LAM)-resistant patients with a suboptimal response to LAM plus adefovir (ADV). METHODS: We retrospectively analyzed the efficacy of switching to tenofovir disoproxil fumarate in suboptimal responders to lamivudine plus adefovir. Charts were reviewed for LAM-resistant chronic hepatitis B (CHB) patients who visited the Zhejiang Province People's Hospital and The First Affiliated Hospital, College of Medicine, Zhejiang University, from June 2009 to May 2013...
March 7, 2015: World Journal of Gastroenterology: WJG
Hongyu Jia, Feng Ding, Jianyang Chen, Yimin Zhang, Dairong Xiang, Jiangshan Lian, Linyan Zeng, Liang Yu, Jianhua Hu, Yongtao Li, Yingfeng Lu, Yuanchun Liu, Lin Zheng, Lanjuan Li, Yida Yang
INTRODUCTION: Among the available nucleos(t)ide analogues adefovir dipivoxil (ADV) is relatively cheap and widely used in rural area in China. However, there are insufficient data on recommendation for patients with suboptimal response to ADV after 48 weeks of treatment in order to reduce the resistance rate in the long term. The aim of this study was to compare the efficacy and safety of LAM add-on combination therapy versus ETV monotherapy for patients with suboptimal response to ADV...
March 2015: Annals of Hepatology
EunYoung Ze, Eun Kyung Baek, Jong Jin Lee, Han Wook Chung, Dae Geon Ahn, Hwan Jun Cho, Jae Cheol Kwon, Hyung Joon Kim, HyunWoong Lee
BACKGROUND/AIMS: Adefovir (ADV) and lamivudine (LAM) combination therapy (ADV+LAM) has been a useful option for patients with LAM-resistant (LAM-r) chronic hepatitis B (CHB). However, the long-term outcomes of LAM+ADV and 1-mg entecavir (ETV) rescue therapies have still been limited. The aim of this study was to determine the long-term outcomes of these two rescue therapies. METHODS: Sixty patients with LAM-r CHB underwent rescue therapy with LAM+ADV (n=36) or 1-mg ETV (n=24)...
September 2014: Clinical and Molecular Hepatology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"